TY - JOUR
T1 - Sex differences in the development of prolactinoma in mice overexpressing hCGB
T2 - Role of TGFB1
AU - Faraoni, Erika Y.
AU - Camilletti, María Andrea
AU - Abeledo-Machado, Alejandra
AU - Ratner, Laura D.
AU - de Fino, Fernanda
AU - Ipo Huhtaniemi, I.
AU - Rulli, Susana B.
AU - Díaz-Torga, Graciela
N1 - Publisher Copyright:
© 2017 Society for Endocrinology Printed in Great Britain.
PY - 2017
Y1 - 2017
N2 - Female transgenic mice that overexpress the human chorionic gonadotrophin B subunit (hCGB+) develop prolactinomas, whereas hCGB+ males do not. The high levels of circulating hCG induce massive luteinization in the ovary of hCGB+ females, and progesterone becomes the primary steroid hormone produced, but estradiol remains at physiological level. The involvement of high levels of progesterone in lactotroph proliferation is not clearly understood; hence, the pathogenesis of prolactinomas in hCGp+ females remains unclear. TGFp1 is an inhibitor of lactotroph function, and the reduced TGFp1 activity found in prolactinomas has been proposed to be involved in tumor development. The aim of the present work was to study the role of TGFp1 in the gender-specific development of prolactinomas in hCGB+ mice. We compared the expression of different components of the pituitary TGFB1 system in males and females in this model. We found reduced TGFB1 levels, reduced expression of TGFB1 target genes, TGFB1 receptors, Ltbpl, Smad4 and Smad7 in hCGB+ female pituitaries. However, no differences were found between the transgenic and wild-type male pituitaries. We postulate that decreased pituitary TGFB1 activity in hCGB+ females is involved in the development of prolactinomas. In fact, we demonstrated that an in vivo treatment carried out for increasing pituitary TGFB1 activity, was successful in reducing the prolactinoma development, and the hyperprolactinemia in hCGB+ females. Moreover, the stronger TGFB1 system found in males could protect them from excessive lactotroph proliferation. Sex differences in the regulation of the pituitary TGFB1 system could explain gender differences in the incidence of prolactinoma.
AB - Female transgenic mice that overexpress the human chorionic gonadotrophin B subunit (hCGB+) develop prolactinomas, whereas hCGB+ males do not. The high levels of circulating hCG induce massive luteinization in the ovary of hCGB+ females, and progesterone becomes the primary steroid hormone produced, but estradiol remains at physiological level. The involvement of high levels of progesterone in lactotroph proliferation is not clearly understood; hence, the pathogenesis of prolactinomas in hCGp+ females remains unclear. TGFp1 is an inhibitor of lactotroph function, and the reduced TGFp1 activity found in prolactinomas has been proposed to be involved in tumor development. The aim of the present work was to study the role of TGFp1 in the gender-specific development of prolactinomas in hCGB+ mice. We compared the expression of different components of the pituitary TGFB1 system in males and females in this model. We found reduced TGFB1 levels, reduced expression of TGFB1 target genes, TGFB1 receptors, Ltbpl, Smad4 and Smad7 in hCGB+ female pituitaries. However, no differences were found between the transgenic and wild-type male pituitaries. We postulate that decreased pituitary TGFB1 activity in hCGB+ females is involved in the development of prolactinomas. In fact, we demonstrated that an in vivo treatment carried out for increasing pituitary TGFB1 activity, was successful in reducing the prolactinoma development, and the hyperprolactinemia in hCGB+ females. Moreover, the stronger TGFB1 system found in males could protect them from excessive lactotroph proliferation. Sex differences in the regulation of the pituitary TGFB1 system could explain gender differences in the incidence of prolactinoma.
KW - HCGβ
KW - Pituitary
KW - Prolactinoma
KW - TGFβ1
UR - http://www.scopus.com/inward/record.url?scp=85014384302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014384302&partnerID=8YFLogxK
U2 - 10.1530/JOE-16-0371
DO - 10.1530/JOE-16-0371
M3 - Article
C2 - 28096433
AN - SCOPUS:85014384302
SN - 0022-0795
VL - 232
SP - 535
EP - 546
JO - Journal of Endocrinology
JF - Journal of Endocrinology
IS - 3
ER -